September 6, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ICU

Core Viewpoint - SeaStar Medical Holding Corporation is facing allegations of issuing materially false and misleading statements regarding its compliance controls and financial reporting, which may lead to a restatement of financial statements and overstated business prospects [1]. Group 1: Allegations and Compliance Issues - The complaint alleges that SeaStar and/or Legacy SeaStar had deficient compliance controls related to the Humanitarian Device Exemption (HDE) Application [1]. - It is claimed that the FDA was unlikely to approve the HDE Application in its current form, and the regulatory prospects of the selective cytopheretic device were overstated [1]. - SeaStar allegedly downplayed the severity of deficiencies in its financial controls while overstating efforts to remediate these issues [1]. Group 2: Financial Reporting Concerns - The company is accused of failing to properly account for the classification of certain outstanding warrants and a prepaid forward agreement [1]. - As a result of these issues, SeaStar is likely to restate one or more previously issued financial statements [1]. - The allegations suggest that the company's public statements were materially false and misleading throughout the relevant period [1]. Group 3: Class Action Participation - Shareholders who purchased shares of SeaStar during the class period from October 31, 2022, to March 26, 2024, are encouraged to register for participation in the class action [2]. - The deadline for seeking lead plaintiff status is September 6, 2024, and there is no cost or obligation to participate [2].